Compare GLDD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | ANAB |
|---|---|---|
| Founded | 1890 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2007 | 2015 |
| Metric | GLDD | ANAB |
|---|---|---|
| Price | $16.94 | $55.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $17.00 | ★ $66.70 |
| AVG Volume (30 Days) | ★ 2.1M | 442.1K |
| Earning Date | 05-26-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.57 | ★ 91.02 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | $234,603,000.00 |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $9.01 | $43.04 |
| P/E Ratio | $15.70 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $7.51 | $15.32 |
| 52 Week High | $16.99 | $63.47 |
| Indicator | GLDD | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 54.46 |
| Support Level | $14.60 | $43.67 |
| Resistance Level | $16.99 | $57.70 |
| Average True Range (ATR) | 0.05 | 3.58 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 65.38 | 25.30 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).